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Abstract: Bullous pemphigoid is the most common autoimmune subepidermal blistering
disease of the skin and mucous membranes. It is also associated with high mortality and poor
prognosis due to advanced age of the patients and coexisting comorbidities. There is a dearth
of data in the literature regarding depression and anxiety among those patients. The objective
of this brief review is to discuss the intertwining relationship between depression and anxiety
with bullous pemphigoid.
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Introduction
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering
disease of the skin and mucous membranes.1 It affects mainly the elderly patients
aged ≥65 years and displays its highest incidence after the age of 90.2,3 In Europe,
its incidence ranges from 2.5 to 42.8 per 10,00,000 person-years.4 BP presents as
tense blisters leaving erosions and crusts and erythema, associated with urticarial
plaques and itch.1–3 BP is also associated with high mortality and poor prognosis
due to advanced age of the patients and comorbidities.5–10 In this brief review, we
discuss the relationships between depression and anxiety with BP (Figure 1).
Quality of Life in Patients with Bullous Pemphigoid
The morbidity of BP and its impact on the quality of life (QoL) are signiﬁcant.1 BP
causes signiﬁcant physical discomfort (itchy patches, blisters, erosions) and physical
limitations. Besides time spent on treatment, ﬁnancial burden (high number of
corticosteroid tubes, nurse at home) and social misconceptions should not be for-
gotten. For a patient treated with the recommended 30 g/day clobetasol propionate
cream protocol,5 the costs for the treatment of one patient with potent topical
corticosteroids during 4 months will be €174.80 ($224.57) in the Netherlands.11
However, this pharmaco-economic evaluation does not include body application by
home care nurses that can substantially increase the total costs.11 Studies have shown
the impact on the QoL of patients with autoimmune bullous diseases (AIBD).12,13
However, most of these studies have focused on pemphigus12,13 or BP patients are
analyzed along with other AIBD.14 To the best of our knowledge, only Kouris et al
have speciﬁcally reported on BP’s impact on QoL. In their series of 57 patients with
BP, they found that patients had higher scores for depression compared to sex- and
gender-matched healthy controls, but did not ﬁnd any difference for anxiety. The
Correspondence: Nicolas Kluger
Department of Dermatology, Skin and
Allergies Hospital, Meilahdentie 2, PO
Box 160, Helsinki 00029 HUS, Finland
Email nicolas.kluger@hus.ﬁ
Clinical, Cosmetic and Investigational Dermatology Dovepress
open access to scientiﬁc and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Clinical, Cosmetic and Investigational Dermatology 2020:13 73–76 73
http://doi.org/10.2147/CCID.S212984
DovePress © 2020 Kluger et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
 
Cl
in
ica
l, 
Co
sm
et
ic 
an
d 
In
ve
st
ig
at
io
na
l D
er
m
at
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
21
4.
14
4.
14
9 
on
 1
3-
M
ar
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
patients had a higher perception of loneliness and social
isolation compared to the controls. There was a positive
correlation between depression and loneliness scores.15 BP
may result in restrictions on work and daily activities,
patients may be concerned about their appearance, the BP
treatment and its probable recurrence.15 It is however
important to stress that the series of patients in the report
by Kouris et al was small and included quite young people.
The mean age was 59 years, which is far from being
representative of the typical population of BP patients
(≥70 years-old). In another small comparative study,
DeGrazia et al found that patients with atopic dermatitis
and BP shared similar experience and QoL impact in rela-
tion to chronic itch.16
A questionnaire speciﬁc to AIBD was recently devel-
oped: the Autoimmune Bullous Disease Quality of Life
(ABQOL). It was found to be more sensitive than the
Dermatology Life Quality Index (DQLI). It explores 17
items including depression, anxiety, relationships, social
life, etc.17 However, we did not ﬁnd any publication about
its use in “real life” with large cohort of BP patients.
Bullous Pemphigoid and
Neurological and Psychiatric
Disorders
BP is associated with various comorbidities including neu-
rological and psychiatric disorders. In Finland, Försti et al
found patients with various central nervous system disor-
ders were at higher risk of developing BP. They included
multiple sclerosis, various forms of dementia, cerebral
strokes, and hemorrhages as well as epilepsy. They also
found various psychiatric conditions, mostly schizophrenia,
and personality disorders, but also bipolar disorders and
major depression as risk factors.18 Association with neuro-
logical conditions and psychiatric disorders have been
observed also in other epidemiological studies.19–21 Link
with psychiatric conditions is not consistently found in
every series.19,22 Bastuji-Garin et al observed that patients
with BP were more likely to have bipolar disorder (4%)
compared with controls.23 Conversely, a large US study
showed that patients with BP that were hospitalized were
more likely to have psychoses or depression (among others)
but no bipolar disorder.24 One appealing hypothesis is that
neurodegeneration or neuroinﬂammation could lead to
a cross-reactive immune response between neural and cuta-
neous antigens and the failure of self-tolerance. Indeed, BP
autoantigens BP180 and BP230 are expressed in the central
nervous system.25 Circulating BP antibodies have been
found in some patients with neurological diseases such as
dementia and Parkinson’s disease but is not known for
patients with psychiatric conditions.25
Drug-Induced Bullous Pemphigoid
Drug-induced BP is a well-known subset of BP.26
Medications to treat any associated comorbidities should
be investigated. Until recently, the list of culprit drugs is
rather small regarding psychiatric disorders. Neuroleptics
have been reported to be associated,27 and anecdotal case
reports have been published with risperidone28 or with
ﬂuoxetine.29 Varpuluoma et al published recently a study
from the Finnish Care Register of Health.30 They found
that a very large number of drugs intended from neurolo-
gic or psychiatric conditions were associated with an
increased risk of BP.30 Drugs that particularly elevated
the risk for BP included periciazine, melperone, haloper-
idol, biperiden, and risperidone. However, adjusted odd
ratio for antidepressants such as escitalopram, venlafaxine
or duloxetine were also signiﬁcantly associated with BP.30
Corticosteroids-Induced Mood
Changes
Superpotent topical corticosteroids are currently the gold stan-
dard treatment.1 However, they may be difﬁcult to initiate
because of the necessity of help at home (partner or other
family members; home nurses). Different national health-care
systems may not be always supportive enough in terms of
costs. Oral corticosteroid can be the ﬁrst choice of treatment in
Bullous
pemphigoid
Anxiety
Depression
Comorbidities
Neurologic and 
psychiatric drug
induced BP
Corticosteroid-
induced
psychiatric
symptoms
Figure 1 Intertwining between depression and anxiety with bullous pemphigoid
and associated comorbidities. Pemphigoid and any associated comorbidities may be
responsible for anxiety or depression. Drugs given to treat anxiety or depression
might be a potential trigger of BP. Additionally, cross-reactive immune responses
between neural and cutaneous antigens may also have an inﬂuence. On the other
hand, systemic corticosteroids to treat bullous pemphigoid may induce psychiatric
complications.
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case of generalized disease.1 Nevertheless, psychiatric side
effects from corticosteroids include mood disorders (mania,
mixed states, depression), anxiety, panic disorders, delirium,
agitation, insomnia or suicidal behaviour.31 Symptoms usually
occur within the ﬁrst 1 to 2 weeks after initiation and are dose
related.31,32 The risk of depression may increase with pro-
longed or chronic exposure.31 The ﬁrst step of treatment in
case of psychiatric corticosteroid-induced symptoms is corti-
costeroid dose reduction or withdrawal.31 In a spirit of com-
pleteness, we wish to remind that both adrenal insufﬁciency33
and Cushing syndrome may present as depression.34
In conclusion, BPmay impact the QoL of the patients with
possible direct effect on anxiety or depression. However, the
review of the literature shows a dearth in terms of publications
on the topic. Depression and anxiety may be related to other
comorbidities, such as dementia.35,36 BP induced by medica-
tions given to treat depression or anxiety should be kept in
mind. Corticosteroids may be associated with acute psychia-
tric symptoms, including depression or anxiety.
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